Belite Bio, Inc
BLTE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $29,939 | $24,844 | $8,869 | $7,419 |
| G&A Expenses | $10,057 | $6,824 | $3,952 | $2,378 |
| SG&A Expenses | $10,057 | $6,824 | $3,952 | $2,378 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $39,996 | $31,668 | $12,821 | $9,797 |
| Operating Income | -$39,996 | -$31,668 | -$12,821 | -$9,797 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3,858 | $45 | $173 | $131 |
| Pre-Tax Income | -$36,138 | -$31,623 | -$12,648 | -$9,666 |
| Tax Expense | $6 | $9 | $0 | $0 |
| Net Income | -$36,144 | -$31,632 | -$12,648 | -$9,666 |
| % Margin | – | – | – | – |
| EPS | -1.18 | -1.19 | -0.63 | -0.4 |
| % Growth | 0.8% | -88.9% | -57.5% | – |
| EPS Diluted | -1.18 | -1.19 | -0.63 | -0.4 |
| Weighted Avg Shares Out | 30,538 | 26,593 | 19,977 | 24,095 |
| Weighted Avg Shares Out Dil | 30,538 | 26,594 | 19,977 | 24,095 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,737 | $74 | $23 | $5 |
| Interest Expense | $20 | $25 | $16 | $0 |
| Depreciation & Amortization | $449 | $399 | $198 | $30 |
| EBITDA | -$35,669 | -$31,199 | -$12,434 | -$9,636 |
| % Margin | – | – | – | – |